Konakion (Phytomenadione)

Phytomenadione serves as a cofactor for gamma‑glutamyl carboxylase, enabling the gamma‑carboxylation of specific glutamate residues on clotting factors II, VII, IX, X and proteins C and S. This modification allows these proteins to bind calcium, which is required for their activation in the coagulation cascade, thereby normalizing hemostasis.

The dose of Konakion is individualized by the prescribing clinician based on the patient’s age, weight, clinical condition, and laboratory parameters. Healthcare professionals determine the appropriate amount and route—intravenous or oral—to achieve the desired therapeutic effect while monitoring safety.

Safety data for phytomenadione in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after careful assessment.

To request Konakion, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Konakion (phytomenadione) is a plant‑derived vitamin K1 formulation available for both intravenous and oral administration, offering rapid correction of deficiency. Compared with synthetic vitamin K analogues, it provides a well‑characterized safety profile and is commonly used where immediate reversal of anticoagulation is required.

Konakion should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from direct sunlight, moisture and extreme temperatures. Inspect the solution for any particulate matter or discoloration before use, and discard if integrity is compromised.

Konakion can be given intravenously as a sterile solution for rapid effect or taken orally as a liquid formulation for longer‑term supplementation. The route, rate of infusion, and volume are determined by the prescriber, who also ensures appropriate monitoring of coagulation parameters.

Serious risks include anaphylactic reactions, severe bleeding despite therapy, and rare thrombotic events. Patients should be observed for signs of hypersensitivity, unexpected hemorrhage, or clot formation, and immediate medical attention should be sought if such symptoms arise.

Konakion is contraindicated in individuals with known hypersensitivity to phytomenadione or any excipients in the formulation. Caution is advised in patients with severe liver disease, uncontrolled bleeding disorders, or those receiving concurrent anticoagulant therapy without appropriate monitoring.